We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Arena Pharmaceuticals, Inc. incurred a loss of $1.98 per share in the first quarter of 2021, narrower than the Zacks Consensus Estimate of a loss of $2.19. The company had incurred loss of $2.00 per share in the year-ago quarter.
Arena recorded no revenues in the reported quarter. The Zacks Consensus Estimates for revenues was pegged at $1 million. The company had recorded revenues of $0.3 million in the year-ago quarter.
Shares of Arena have lost 16.3% so far this year compared with the industry’s 6% decrease.
Quarter in Details
Research & development (R&D) expenses escalated 30.6% from the prior-year level to $102.5 million, primarily as a result of the progress of its pipeline candidate, etrasimod, to the next phase of clinical development.
Selling, general and administrative expenses increased 11.7% from the year-ago figure to $29.5 million.
The company ended the quarter with approximately $1.1 billion in cash, cash equivalents and investments balance, same as of Sep 30, 2020.
Pipeline Update
In March, Arena announced that a mid-stage study evaluating its cannabinoid receptor 2 agonist candidate, olorinab, in patients with abdominal pain due to irritable bowel syndrome (IBS) failedto meet the primary endpoint. Further development of the candidate is now subject to regulatory approval.
Arena has another candidate, etrasimod, in its pipeline that is being developed for multiple indications in separate clinical studies. It also has two early-stage candidates, ADP418 and temanogrel.
Etrasimod is presently in late-stage development for ulcerative colitis. Arena is evaluating the candidate in the pivotal phase III ELEVATE UC 52 study and another phase III study — ELEVATE UC 12 — as a treatment for moderately-to-severely active ulcerative colitis ("UC"). Top-line data from both studies are expected in the first quarter of 2022.
During the first quarter, the company initiated a phase IIb study — VOYAGE — to evaluate etrasimod in patients with eosinophilic esophagitis (EoE).
The company is also evaluating the candidate in the phase IIb/III CULTIVATE study in patients with Crohn's disease. A phase II study is evaluating etrasimod in alopecia areata (AA) patients. The company is advancing the candidate to a phase III registrational program to evaluate it as a potential treatment for atopic dermatitis.
The temanogrel program was announced in January at the JP Morgan Health Care Conference. It will be developed for treating coronary microvascular obstruction disease. A phase II study is under planning.
Arena Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Atea’s earnings per share estimates have moved up from $3.79 to $8.34 for 2021 and from $16.76 to $17.25 for 2022 in the past 30 days. The stock has soared 757.3% in the past year.
Kiniksa’s loss per share estimates narrowed from $2.70 to $2.62 for 2021 and from $2.40 to $2.07 for 2022 in the past 30 days.
Nabriva’s loss per share estimates narrowed from $2.03 to $1.95 for 2021 and from $1.35 to $1.22 for 2022 in the past 30 days. The company delivered an earnings surprise of 46.50%, on average, in the last four quarters.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Arena (ARNA) Q1 Earnings Beat Estimates, Etrasimod Progresses
Arena Pharmaceuticals, Inc. incurred a loss of $1.98 per share in the first quarter of 2021, narrower than the Zacks Consensus Estimate of a loss of $2.19. The company had incurred loss of $2.00 per share in the year-ago quarter.
Arena recorded no revenues in the reported quarter. The Zacks Consensus Estimates for revenues was pegged at $1 million. The company had recorded revenues of $0.3 million in the year-ago quarter.
Shares of Arena have lost 16.3% so far this year compared with the industry’s 6% decrease.
Quarter in Details
Research & development (R&D) expenses escalated 30.6% from the prior-year level to $102.5 million, primarily as a result of the progress of its pipeline candidate, etrasimod, to the next phase of clinical development.
Selling, general and administrative expenses increased 11.7% from the year-ago figure to $29.5 million.
The company ended the quarter with approximately $1.1 billion in cash, cash equivalents and investments balance, same as of Sep 30, 2020.
Pipeline Update
In March, Arena announced that a mid-stage study evaluating its cannabinoid receptor 2 agonist candidate, olorinab, in patients with abdominal pain due to irritable bowel syndrome (IBS) failedto meet the primary endpoint. Further development of the candidate is now subject to regulatory approval.
Arena has another candidate, etrasimod, in its pipeline that is being developed for multiple indications in separate clinical studies. It also has two early-stage candidates, ADP418 and temanogrel.
Etrasimod is presently in late-stage development for ulcerative colitis. Arena is evaluating the candidate in the pivotal phase III ELEVATE UC 52 study and another phase III study — ELEVATE UC 12 — as a treatment for moderately-to-severely active ulcerative colitis ("UC"). Top-line data from both studies are expected in the first quarter of 2022.
During the first quarter, the company initiated a phase IIb study — VOYAGE — to evaluate etrasimod in patients with eosinophilic esophagitis (EoE).
The company is also evaluating the candidate in the phase IIb/III CULTIVATE study in patients with Crohn's disease. A phase II study is evaluating etrasimod in alopecia areata (AA) patients. The company is advancing the candidate to a phase III registrational program to evaluate it as a potential treatment for atopic dermatitis.
The temanogrel program was announced in January at the JP Morgan Health Care Conference. It will be developed for treating coronary microvascular obstruction disease. A phase II study is under planning.
Arena Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Arena Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Arena Pharmaceuticals, Inc. Quote
Zacks Rank and Stocks to Consider
Arena currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the drug/biotech sector are Atea Pharmaceuticals, Inc. (AVIR - Free Report) , Kiniksa Pharmaceuticals, Ltd. (KNSA - Free Report) and Nabriva Therapeutics AG , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Atea’s earnings per share estimates have moved up from $3.79 to $8.34 for 2021 and from $16.76 to $17.25 for 2022 in the past 30 days. The stock has soared 757.3% in the past year.
Kiniksa’s loss per share estimates narrowed from $2.70 to $2.62 for 2021 and from $2.40 to $2.07 for 2022 in the past 30 days.
Nabriva’s loss per share estimates narrowed from $2.03 to $1.95 for 2021 and from $1.35 to $1.22 for 2022 in the past 30 days. The company delivered an earnings surprise of 46.50%, on average, in the last four quarters.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
AccessZacks Top 10 Stocks for 2021 today >>